AS-023: Efficacy and Safety of a Novel Non-Symmetrical, Biodegradable Polymer-Coated Sirolimus-Eluting Stent in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Feng Zhang,Yuhua Zheng,Juying Qian,Lei Ge,Junbo Ge

DOI: https://doi.org/10.1016/j.amjcard.2012.01.017

2012-01-01

Abstract:Objective To compare a novel non-symmetrical,biodegradable polymer-coated sirolimus-eluting stent(NSBP-SES) with a traditional symmetrical,durable polymer-coated sirolimus-eluting stent(SDP-SES) during percutaneous coronary intervention(PCI),and to evaluate its efficacy and safety in patients with ST-segment elevation myocardial infarction(STEMI).Methods From January 2007 to December 2009,NSBP-SES was implanted in 171 patients(experimental group) and SDP-SES in 249 patients(control group) during primary PCI for STEMI.All the patients were followed up for one year postoperatively.Results There was no significant difference in the incidence rate of 12-month target lesion failure(TLF) between experimental group and control group(5.8% vs.5.6%,P0.05);neither were the death,cardiac death,non-fatal re-infarction,target vessel revascularization,or target vessel failure(all P0.05).Subacute stent thrombosis occurred in 1 patient in experimental group and in 3 patients in control group.Late stent thrombosis occurred in another patient in control group.Conclusion There are no significant differences in efficacy and safe between NSBP-SES and SDP-SES during primary PCI for STEMI.Further investigation is warranted to validate the long-term clinical outcomes.